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Abstract
Objective—Obesity is a strong risk factor for breast cancer in postmenopausal women and
adverse prognostic indicator regardless of menopausal status. Leptin is an important regulator of
adipose tissue mass and has been associated with tumor cell growth. Leptin exerts its effects
through interaction with the leptin receptor (LEPR). We investigated whether genetic variations in
the leptin (LEP) and LEPR genes are associated with risk of breast cancer, or once diagnosed,
with survival.
Methods—The polymorphisms LEP G-2548A and LEPR Q223R were characterized in
population-based study consisting of mostly European-American women. The study examined
1,065 women diagnosed with first, primary invasive breast cancer between 1996 and 1997.
Controls were 1,108 women frequency matched to the cases by 5-year age group.
Results—A modest increase in risk of developing breast cancer was associated with the LEP
-2548AA genotype when compared to the LEP -2548GG genotype (age-adjusted OR=1.30; 95%
CI=1.01–1.66). This association was stronger among postmenopausal women who were obese
(OR=1.86; 95% CI=0.95–3.64) although the interaction was of borderline statistical significance
(P=0.07). We found no evidence of an association with polymorphisms of either LEP or LEPR in
relation to all-cause or breast cancer-specific mortality among women with breast cancer (mean
follow-up time=66.7 months). The effects of these genotypes on breast cancer risk and mortality
did not vary significantly when stratified by menopausal status.
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Conclusions—In summary, our results show that a common variant in LEP may be associated
with the risk of developing breast cancer supporting the hypothesis that leptin is involved in breast
carcinogenesis.
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Introduction
Obesity is a growing public health problem with increasing incidence and prevalence not
only in the United States, but also worldwide [1]. Previous reports on the relationship
between obesity and breast cancer have consistently shown an increased risk in
postmenopausal women, but little evidence of an increase in premenopausal women [2].
Among breast cancer patients, obesity at diagnosis has been consistently shown to adversely
affect survival among both pre-and postmenopausal women [3]. The mechanism by which
obesity exerts its effects is thought to be through endogenous hormone pathways,
particularly through increased production of estrogens that occur through conversion of
androstenedione in peripheral adipose tissue [4].
Obesity is caused by a chronic energy imbalance and is thought to be regulated in large part
by the leptin-signaling pathway which, together with insulin, regulates medium- to long-
term food intake and energy expenditure [5]. White adipose tissue is the primary production
site of leptin, which is found in circulation and is considered one of the main signals that
affect food intake and body weight. It is encoded by the leptin (LEP) gene [6] and its
expression and secretion are highly correlated with body fatness and adipocyte size [7].
Leptin exerts its biologic effects through selective binding with the leptin receptor (LEPR),
which is expressed in many tissues, including the mammary gland [8].
In addition to its role in obesity, leptin has also been shown to stimulate the growth of
human breast cancer cells in vitro and has shown angiogenic qualities that acts through
regulation of vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGF-R2)
expression [9,10]. Furthermore, leptin may modify estrogenic activity by inducing
aromatase activity, thereby increasing the amount of androstenedione converted to estrone in
adipose tissue [11,12]. Results from epidemiologic studies of breast cancer, however, have
provided little evidence for an association with circulating leptin levels [13–15].
Genetic mutations of LEP and LEPR in mice have been shown to produce a phenotype
resulting in morbid obesity [6,16,17]. In humans, LEP and LEPR polymorphisms, including
a G to A substitution at nucleotide -2548 upstream of the ATG start site of LEP (G-2548A)
and an A to G substitution at codon 223 in exon 6 (Q223R) of LEPR [18–20], may be
related to obesity, as well as enhanced gene expression and increased circulating levels of
leptin [20,21].
To assess the associations between LEP and LEPR polymorphisms and risk of developing
breast cancer and subsequent survival, we used data from the Long Island Breast Cancer
Study Project (LIBCSP). In addition, we evaluated whether the breast cancer associations
with LEP and LEPR polymorphisms varied according to body mass index (BMI).
Materials and methods
This study draws upon data that was collected from participants as part of the LIBCSP, a
population-based study of English-speaking residents of Nassau and Suffolk counties of
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Long Island, NY [22]. The study reported here utilizes resources from both the case-control
and follow-up studies of the LIBCSP, as described below.
Study Population
Case-control study—Eligible case participants were women newly diagnosed with a
first, primary in situ or invasive breast cancer between August 1, 1996, and July 31, 1997.
Cases were identified using a rapid reporting system established specifically for the LIBCSP
and were confirmed by physicians’ and medical records. The attending physician was
contacted to confirm study eligibility and to seek permission to contact the patient. Controls
were women who were residents of the same two counties, frequency-matched by 5-year
age group to the expected age distribution of cases. Potentially eligible control women were
identified by Waksberg’s method of random digit dialing (RDD) [23] for those under 65
years of age, and by Health Care Finance Administration (HCFA) rosters for those 65 years
of age and older. Institutional Review Board (IRB) approval of the study protocol was
obtained from each collaborating institution and participating hospital and written informed
consent was obtained from each participant prior to the interview. A total of 1,508 women
with breast cancer, of which 1,273 had invasive breast cancer, and 1,556 control women
participated in the case-control study interview.
Follow-up study—Vital status through the end of 2002 among the case women (n = 1508)
was determined through the National Death Index (NDI).
Data collection
Baseline, case-control data—The lifetime weight and most of the covariate data used
in this analysis were collected as part of the LIBCSP baseline case-control interview. The
main questionnaire was administered in-home by a trained interviewer and took
approximately 2 h to complete. Information obtained from the main questionnaire includes
reproductive and menstrual history, exogenous hormone use, family history of cancer,
physical activity, smoking history, alcohol intake, and demographic characteristics (http://
epi.grants.cancer.gov/LIBCSP/projects/Questionnaire.html). Descriptive characteristics for
the entire LIBCSP study have been previously published [22].
After completing the interview and an additional informed consent form, participants were
asked to donate blood samples. From each participant, about 40 cc of blood was obtained (5
EDTA-treated lavender-top tubes). The number of control women with a completed
interview who donated a blood sample was 1,141 (73.3%). Among women with available
DNA (1,065 cases and 1,108 controls), women were primarily Caucasian (94.4, 92.4%,
respectively), postmenopausal (67.3, 64.6%), had at least a high school diploma (88,
91.5%), and had never used hormone replacement therapy (HRT) (70.3, 72.3%) [22].
Additionally, as part of the baseline case-control study, medical records of the cases were
abstracted for tumor stage, estrogen receptor (ER) status, progesterone receptor (PR) status,
and initial course of treatment.
Follow-up data among case women—Follow-up information on completed course of
treatment for the initial breast cancer diagnosis was obtained by trained interviewer via
telephone from 1,098 case participants or their proxy (8%) in 2002–2004. There were 410
cases without follow-up interview data due to nonresponse, refusal, were untraceable or
were deceased without an identifiable proxy.
As part of the LIBCSP follow-up, updated medical records were retrieved and abstracted for
598 (39.8%) women. Trained abstractors reviewed medical records to determine each
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participant’s tumor size and nodal status information for their initial breast cancer diagnosis.
In addition, medical records were reviewed to determine the treatment regimen for each
breast cancer case and this data was compared with the respondent’s self-reported treatment
regimen from the baseline interview and from the follow-up interview. A high concordance
was found between information abstracted from medical records and self-reported radiation
therapy (Kappa=0.97), chemotherapy, (Kappa=0.96) and hormone therapy (Kappa=0.92).
Thus, self-reported treatment at the baseline and follow-up interviews was used for this
analysis.
Study outcome for the follow-up analyses—For the LIBCSP follow-up study, the
National Death Index (NDI) was used to ascertain all-cause and breast cancer-specific
mortality among case participants. Case participants were followed from diagnosis until
December 31, 2002 for a mean of 66.7 months (range, 2.7 – 88.6). Among the 1,508 women
diagnosed with breast cancer, 198 (13.1%) deaths occurred. Based on International
Classification of Diseases (ICD) codes 174.9 and C-50.9 listed as a primary or secondary
code on the death certificate, 128 (64.6%) deaths were due to breast cancer. There were nine
additional cancer deaths arising in areas of common breast tumor metastases, including the
brain and lung. Cardiovascular disease was the second most common cause of death,
accounting for 21% of all deaths.
Genotyping
DNA was isolated from blood cells and genotyped with the use of template-directed primer
extension with detection of incorporated nucleotides by fluorescence polarization in a 96
microwell-based format. Master DNA 96 well plates containing 10 ng/μl were used to make
replica plates containing 25 ng DNA/well. For polymerase chain reaction (PCR)
amplification, the primers for LEP G-2548A (rs7799039) (forward 5′-
TCCCGTGAGAACTATTCTTCTTTTG-3′, reverse 5′-
CCTGCAACATCTCAGCACTTAGG-3′) and for LEPR Q223R (rs1137101) (forward 5′-
AACAGCCAAACTCAACGACA-3′, reverse 5′-GCCACTCTTAATACCCCCAGT-3′)
gave 93 and 251 bp products, respectively. Conditions for amplification were 0.2μl (10
pmol/ μl) forward and reverse primers, 0.2 μl 25mM MgCl2 (only for LEPR), 1 μl 10× PCR
buffer, 0.1 μl (5u/ml)Taq polymerase (Roche Molecular Biochemicals, Indianapolis, IN),
0.2 μl (10mM) dNTPs (Roche) and water added to the total volume of 10 μl.
Thermocycling conditions for LEP G-2548A were initial denaturation at 94° for 5 min
followed by 35 cycles of 94° for 30 s, 60.5 ° for 35 s72 ° for 30 s, followed by final
extension at 72 ° for 5 min. Thermocycling conditions for LEPR Q223R were initial
denaturation at 94 ° for 5 min followed by 35 cycles of 94° for 30 s 60 ° for 45 s, 72 ° for 30
s, followed by final extension at 72 ° for 5 min. Primers and dNTPs were digested with 1
unit of shrimp alkaline phosphatase (1u/μl, Roche) after the addition of 1 μl of 10×
SAPbuffer and 1 unit E.Coli exonuclease I (10 u/ μl, United States Biochemical, Cleveland,
OH) and 7.9 μl of water for 45 min at 37°, followed by heating at 95° for 15 min. Forward
extension primers were SNPS 5′-TTGTTTTGCGACAGGGTTGC-3′ and 5′-
ATCACATCTGGTGGAGTAATTTTCC-3′ for LEP and LEPR, respectively. Acycloprime
FP SNP Detection kit C/T contained the ddNTPs labelled either with R110 or TAMRA
(Perkin Elmer Life Sciences, Boston MA). To 7 μl of reaction mixture was added 0.05 μl
Acycloprimer enzyme, 1 μl C/T Terminator mix, 2 μl 10× reaction buffer, 0.5 μl extension
primer (10 pmol/ μl) and 9.45 μl water. Extension was carried out by heating at 95° for 2
min followed by 30 cycles for LEP G-2548A and 20 cycles for LEPR of 95° for 15 s and
55° for 30 s. Plates were read on a Perkin Elmer Victor instrument. In addition to assay
specific quality control samples, 10% of samples were reassayed after relabeling to keep
laboratory personnel blinded to identity.
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The genotype distributions of the LEP -G2548A and LEPR Q223R genotypes were in
Hardy-Weinberg equilibrium among controls (P=0.12 and 0.33, respectively). The
frequencies of the common alleles among control women for the LEP and LEPR genotypes
were consistent with those found in other Caucasian populations [24–26].
Statistical methods
Case-control analyses—Odds ratios (ORs) and 95% confidence intervals (CI) were
calculated using unconditional logistic regression models [27] with the statistical software
package SAS version 8.1 (SAS Institute Inc., Cary, NC). All models were adjusted for age at
diagnosis. Additional factors considered as potential confounders included: variables related
to demographic factors (race, income, education, marital status, religion), reproduction
(parity, age at first live birth, breast feeding), and menstruation (age at menarche,
menopausal status), exogenous hormone use was also considered (hormonal birth control,
hormone replacement) as was medical history (benign breast disease, family history of
breast cancer), and lifestyle factors (alcohol consumption, dietary fat and total caloric intake,
cigarette smoking, BMI and physical activity). Using manual backward elimination,
potential confounders were removed from models beginning with those with the highest P-
value. Variables remained in the final models if their inclusion changed the estimate of
effect by >10% [27].
Effect measure modification on the multiplicative scale between categorical body size
variables and other covariates was evaluated using the log likelihood ratio test to compare
logistic regression models with and without the cross-product terms [28]. Body size
measures included BMI in the year prior to diagnosis which was categorized based on
World Health Organization guidelines [29]. Because there were very few cases considered
to be underweight (BMI <18.5) and including them in the reference group did not alter the
results, three levels of BMI were used to categorize women: ideal weight (BMI <24.9);
overweight (BMI 25–29.9); obese (BMI ≥ 30). Menopausal status was determined using
information provided by the subject about the date of her last menstrual period, prior
surgical information on hysterectomy and oophorectomies, cigarette smoking status, and use
of hormone replacement [22]. Postmenopausal status was defined as having a last menstrual
period more than 6 months before the reference date or if both ovaries were removed before
the reference date. For women with unknown menopausal status, women were categorized
as postmenopausal based on the 90th percentile for age at menopause in the control
population, calculated according to smoking status; these women were categorized as
postmenopausal if the age at reference was ≥54.8 years of age and a smoker, and ≥55.4
years if a nonsmoker. We were unable to assign menopausal status to 3.2% of women (30
cases, 63 controls), who were excluded from analyses specific to menopausal status.
Survival analysis—Cox proportional hazards regression [28] was used to estimate Hazard
Ratios (HR) and 95% confidence intervals (CI) for the risk of all-cause and breast cancer-
specific mortality. The results for overall and 5-year survival were similar; therefore only
overall survival is reported.
Effect measure modification on the multiplicative scale between genotype and selected
covariates was evaluated using the log likelihood ratio test to compare proportional hazards
regression models with and without the cross-product terms [28]. We evaluated models
stratified by obesity at diagnosis (<30, 30+) and menopausal status (premenopausal,
postmenopausal). Associations were also evaluated by stratification on the tumor
characteristics, ER status (negative, positive), PR status (negative, positive), tumor stage (in
situ, invasive), nodal status (node-negative, node-positive) and tumor size (<2 cm, ≥2 cm).
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All models were adjusted for age at diagnosis. In addition to consideration of the covariates
listed above for the case-control analyses, for the survival analyses we also considered as
potential confounders other factors including history of comorbidities reported at the
baseline interview (high cholesterol, history of blood clots, diabetes, hypertension, previous
myocardial infarction and stroke), tumor characteristics (tumor stage, tumor size and nodal
status) and treatment undergone for the original breast cancer diagnosis. Adjustment for
covariates did not alter the estimates of effect by more than 10% and therefore associations
reported are adjusted for age only.
To further explore possible confounding by tumor characteristics, we conducted separate
analyses restricted to women for whom we have complete tumor characteristic and tumor
treatment data. There were no differences in the estimated effects or evidence of
confounding by these variables for the relationship between genotype and mortality (data
not shown).
Results
Case-control analysis
A 30% increased association was observed in subjects with the LEP -2548AA genotype
compared to those with the LEP -2548GG genotype (OR=1.30; 95% CI=1.01–1.66) (Table
1). No significant association emerged for LEPR Q223R genotypes. Adjustment for
covariates did not materially alter these associations. Results were similar for both pre- and
postmenopausal women (data not shown).
We explored the potential interaction between LEP G-2548A and LEPR Q223R genotypes
(Table 2). There was little evidence of effect modification of the LEP -G2548A genotype by
LEPR Q223R. Although the OR for having the LEP -2548AA genotype was slightly
stronger among those who carried the LEPR 223GG genotype (OR=1.54; 95% CI=1.00–
2.37), we did not observe statistically significant interaction between the two
polymorphisms in the case-control analyses (P=0.57).
We also conducted analyses to determine the influence of obesity on the relationship
between the LEP and LEPR polymorphisms and breast cancer in both pre- and
postmenopausal women (Table 3). There was no evidence that the estimated risks for
carrying the LEP -2548AA genotype differed according to obesity status among
premenopausal women. However, among postmenopausal women who were considered
obese at diagnosis (BMI≥30), there was a moderate increase in the risk estimate for women
with the LEP -2548AA genotype (OR=1.86; 95% CI=0.95–3.64) when compared to women
who have the LEP -2548GG genotype, although the interaction was not statistically
significant on the multiplicative scale (P=0.07). There was no evidence for modification by
BMI of the association between LEPR genotypes and breast cancer risk.
Survival analysis
We evaluated the relation between the LEP -G2548A and LEPR Q223R genotypes and
mortality (Table 4). There was little or no association between the LEP -G2548A or LEPR
Q223R genotypes on the risk of either breast cancer-specific or overall death.
Additional survival analyses to determine associations with breast cancer mortality of the
LEP -G2548A or LEPR Q223R genotypes were conducted according to tumor prognostic
factors such as stage, node status, tumor size or ER and PR status (data not shown). No
meaningful associations were observed for most indicators for either the LEP or LEPR
genotypes. Only PR status was found to be related to the LEP polymorphism, where breast
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cancer cases with the LEP -2548AA genotype were observed to have a higher frequency of
PR positive tumors (P=0.03).
Discussion
In this large population-based study, women with the LEP -2548AA genotype were
observed to have a 30% increased risk of developing breast cancer, an association that was
not modified by menopausal status. Although there was some suggestion that the effect was
stronger among obese postmenopausal women, the interaction was not statistically
significant. The LEP -2548AA genotype was not, however, associated with survival among
those with a breast cancer diagnosis. We were not able to demonstrate an effect of the LEPR
Q223R polymorphism on breast cancer development or prognosis.
Leptin is thought to be a growth factor and has been associated with stimulation of normal
and tumor cell growth, tumor migration and invasion, enhanced aromatase activity and
involvement with angiogenesis (reviewed in [9]). Higher circulating levels of leptin have
been directly correlated with BMI and insulin, and have been associated with prognostic
indicators such as advanced tumor stage, a higher tumor grade at diagnosis, as well lack of
expression for both estrogen and progesterone receptors [30]. There is recent evidence that
leptin is expressed in both normal and cancerous mammary tissue, however LEPR is
generally only detected in mammary carcinoma cells [31]. When found in tumors, both
leptin and LEPR are strongly associated with poorer prognosis having higher occurrence of
distant metastasis and lower survival [31]. There is further evidence that tumors expressing
LEPR have a worse prognosis among those who also have a high serum or mRNA levels of
leptin [32]. These observations have lent support to the suggestion that leptin may play a
role in breast cancer etiology and prognosis.
One hospital-based study conducted in Tunisia has reported on the LEP G-2548A and LEPR
Q223R polymorphism genotypes [33]. This Tunisian sample of 308 cases and 222 controls
reported a threefold increase in risk of developing breast carcinoma for those who carried
the LEP -2548AA genotype (OR=3.17; 95% CI=1.47–6.96), with GA heterozygous carriers
having an intermediate risk (OR=1.45, 95% CI=0.99–2.11), compared with women who
were homozygous for the LEP -2548 G allele. In our population-based sample of mostly
European-American women we observed that the LEP -2548AA genotype was associated
with a somewhat more modest 30% increase in the risk of developing breast cancer when
compared to those with the LEP -2548GG genotype. We did not, however, observe an
increased association with breast cancer risk for carrying a single A allele. Whether the
differences in the magnitude of the association with the LEP genotype between the two
studies is due to differences in ethnicity, or the differences in sample size, is not clear. While
the functional status of the LEP G-2548A polymorphism is unknown, previous reports have
indicated that the A allele is associated with increased mRNA expression and higher
circulating levels of leptin [21]. Additionally, the A allele of the LEP -2548 polymorphism
has also been linked to other cancers, such as those of the lung and prostate [24,34].
Circulating leptin levels have been associated with cancers of the lung and prostate and with
non-Hodgkin lymphoma [24,34,35]. However, despite evidence that leptin stimulates breast
cancer cell proliferation in vitro [36], epidemiologic support for the association of
circulating leptin levels in breast cancer development and progression has been limited. One
investigation found an inverse relationship with breast cancer development in
premenopausal women only [14], whereas no association was observed in two other studies
[15,37]. With regard to breast cancer prognosis, one study reported no association between
leptin levels and either disease-free or overall survival [30]. Why these studies failed to
show evidence that leptin levels are associated with breast cancer is unclear. One possibility
Cleveland et al. Page 7
Breast Cancer Res Treat. Author manuscript; available in PMC 2013 February 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
may be that the leptin levels in these studies were measured in circulation which could vary
substantially from tissue concentrations found in the breast.
Although systemic levels of leptin do not appear to be associated with breast cancer risk,
there has been shown to be a positive correlation between circulating levels and tumor levels
[32] and there is evidence that leptin and leptin receptor play a role in breast cancer locally
[31]. The Tunisian study by Snoussi et al. found an increased risk of breast cancer and worse
prognosis among women carrying the R variant of the LEPR Q223R polymorphism [33]
while another small Korean study found no association for the leptin receptor variant
(OR=0.59; 95% CI=0.19–1.81) [38]. In our study we were not able to show a relationship
between the LEPR Q223R polymorphism and either breast cancer risk or prognosis, which
is consistent with two [39,40] of three [20] previous studies which show a lack of an
association with serum leptin levels. Our lack of association between the LEPR Q223R
polymorphism and breast cancer risk and prognosis may be due to a lack of functionality of
the polymorphism. A recent study found no association between serum leptin concentrations
and LEPR Q223R genotypes [38] and a recent meta-analysis of 18 studies indicated that
there is no association between the LEPR Q223R polymorphism and obesity [41]. We were
not, however, able to confirm whether circulating levels of leptin are associated with
variants of LEP and LEPR, as serum leptin levels were not measured in this study.
We observed a slightly increased association with breast cancer risk for the LEP -2548AA
genotype among obese postmenopausal subjects (BMI≥30), an interaction that approached
statistical significance (P=0.07). BMI is a well-known risk factor for breast cancer in
postmenopausal women and is also negatively associated with survival among both pre- and
postmenopausal breast cancer cases [42]; these observations have been confirmed among the
LIBCSP participants in our study [43,44]. Leptin is a key hormone in obesity and regulation
of energy balance, and whose levels are highly correlated with fat mass and BMI [45]. Due
to the close correlation of leptin and BMI, we hypothesized that the association between the
LEP and LEPR genotypes association with higher levels of circulating leptin and breast
cancer might behave similarly. However, while the effects of BMI on breast cancer risk
differ according to menopausal status (with obesity often associated with a decreased risk of
breast cancer in premenopausal women [2]), we did not observe any difference in the
association between LEP and LEPR and breast cancer risk according to menopausal status,
although there was some suggestion that the effect of the LEP AA genotype was modified
by obesity among postmenopausal women only.
To the best of our knowledge this is the first report among European-American women that
a variant in the promoter region of the LEP gene at locus -2548 is associated with a 30%
increase in risk of breast cancer development, and the association may be more profound
among obese women. These results should be confirmed in additional studies to further
evaluate the potential interaction between this polymorphism, obesity and breast cancer
development.
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Table 1
LEP (G-2548A) and LEPR (Q223R) genotype ORs and 95% CI in breast cancer cases and controls in the
Long Island Breast Cancer Study Project
Genotype Cases (%) Controls (%) OR* (95% CI)
LEP G-2548A
GG 341 (32) 360 (33) Ref.
GA 492 (47) 561 (51) 0.91 (0.75–1.10)
AA 226 (21) 180 (16) 1.30 (1.01–1.66)
LEPR Q223R
AA 173 (16) 187 (17) Ref.
AG 521 (50) 551 (50) 1.00 (0.78–1.27)
GG 355 (34) 360 (33) 1.04 (0.81–1.34)
*
Odds ratio (OR) adjusted for age
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